Met with Exec Chairman Ross Haggighat and newly appointed CEO Michael Thomas who have very impressive CV's filled with successful outcomes in the M & A area, these guys are not in this company on a whim and a prayer....they have come in at a pivotal time when $$$$opportunity is offered to them and their US investor networks.
Simply put:
1. They have delivered on all proposed timetables and outcomes they have tabled in the 8 months since they put the broom through the company. 2. They have a path that will see the company strengthen it's innovation acceptance at the highest levels in the hospital/doctor sector. 3. Sales are not the game plan now and should be something we focus on in 12 months when the licensing partnerships are achieving coal face approval and acceptance. 4. Funding to come from US based financiers with stock placed at a premium rather than a discount as is done here in Australia......expect this sometime in September as we get closer to US listing. 5. Opportunity for Australian investors to average or position in at low levels. 6. Re-naming of company to Isonea to co-incide with US listing. 7. Concerted marketing push with several large investor networks soaking up trader stock while a solid news flow unfolds over the next 2 months. 8. Expected nailing of a large licensing partnership very near as well as US analyst's reports outlining company's future potential.
The presentation says it all, but the calibre of the management is nothing short of world class, Ross and Mike are the real deal and this company will become a world leader......probably with the Yanks owning and buying a lot more of the stock than us Aussie's as we are more focused on resources, just MHO.
Good luck to all, I am a bigger believer than ever but ask you please DYOR.
Regards
Eyeknow
KSX Price at posting:
1.1¢ Sentiment: Buy Disclosure: Held
